Skip Navigation


CIT can broadcast your seminar, conference or meeting live to a world-wide audience over the Internet as a real-time streaming video. The event can be recorded and made available for viewers to watch at their convenience as an on-demand video or a downloadable podcast. CIT can also broadcast NIH-only or HHS-only content.

The two faces of the IL-15- Janus Kinase-Stat system: implications for the immunotherapy of autoimmune diseases and cancer

Loading video...

404 Views  
   
Air date: Wednesday, November 29, 2017, 3:00:00 PM
Time displayed is Eastern Time, Washington DC Local
Views: Total views: 404, (154 Live, 250 On-demand)
Category: WALS - Wednesday Afternoon Lectures
Runtime: 01:09:28
Description: NIH Director's Wednesday Afternoon Lecture Series

Dr. Walmann will present the annual William Paul lecture. Dr. Waldmann defined the IL-2 receptor alpha and beta subunits using the daclizumab antibody he discovered, an antibody that is approved by the FDA. He co-discovered IL-15 and performed the first in-human clinical trial with this agent in patients with malignancy. Furthermore, Waldmann defined molecular abnormalities of the common gamma cytokine, Jak/Stat signaling pathway in HTLV-1 associated adult T-cell lymphoma and translated this discovery with a trial of a Jak inhibitor in patients with this disorder.

For more information go to https://oir.nih.gov/wals
Debug: Show Debug
NLM Title: The two faces of the IL-15- Janus Kinase-Stat system : implications for the immunotherapy of autoimmune diseases and cancer / Thomas A. Waldmann.
Author: Waldmann, Thomas.
Publisher:
Abstract: (CIT): NIH Director's Wednesday Afternoon Lecture Series Dr. Walmann will present the annual William Paul lecture. Dr. Waldmann defined the IL-2 receptor alpha and beta subunits using the daclizumab antibody he discovered, an antibody that is approved by the FDA. He co-discovered IL-15 and performed the first in-human clinical trial with this agent in patients with malignancy. Furthermore, Waldmann defined molecular abnormalities of the common gamma cytokine, Jak/Stat signaling pathway in HTLV-1 associated adult T-cell lymphoma and translated this discovery with a trial of a Jak inhibitor in patients with this disorder.
Subjects: Autoimmune Diseases--therapy
Interleukin-15--immunology
Interleukin-15--therapeutic use
Janus Kinases
Neoplasms--therapy
STAT Transcription Factors
Publication Types: Lectures
Webcasts
Download: To download this event, select one of the available bitrates:
[64k]  [150k]  [240k]  [440k]  [740k]  [1040k]  [1240k]  [1440k]  [1840k]    How to download a Videocast
Caption Text: Download Caption File
NLM Classification: QW 568
NLM ID: 101718226
CIT Live ID: 26622
Permanent link: https://videocast.nih.gov/launch.asp?23610